Verona Pharma plc Verona Pharma Appoints Dr. Desiree Luthman As Vice President Of Regulatory Affairs

 
TIDMVRP TIDMVRP 
 
 
 
   LONDON, June 22, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) 
(NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on developing and commercializing innovative therapies 
for respiratory diseases, today announces the appointment of Desiree 
Luthman, DDS to the Company's executive team as Vice President, 
Regulatory Affairs. 
 
   Dr. Luthman's experience during the last two decades includes a series 
of roles leading regulatory affairs teams and strategies for 
pharmaceutical products spanning from early development to post-approval 
marketing. Throughout her career, Dr. Luthman has held regulatory 
positions at large global pharmaceutical and biotechnology companies, 
including Bristol-Meyers Squibb, Celgene and AstraZeneca. Prior to 
joining Verona Pharma, Dr. Luthman directed regulatory activities 
related to pulmonary disease at Sanofi and most recently led their 
regulatory team through the FDA approval of dupilumab for atopic 
dermatitis in the United States. Dr. Luthman earned her Doctor in Dental 
Sciences from the Karolinska Institute in Sweden. 
 
   "We welcome Desiree to our growing Verona Pharma team," said Jan-Anders 
Karlsson, PhD, CEO of Verona Pharma. "She has an accomplished track 
record of working closely with the FDA and EMA on behalf of 
international healthcare companies to achieve key regulatory milestones. 
Her vast experience will be instrumental as we advance our regulatory 
plans in the U.S. and Europe under her leadership in our effort to 
deliver important new therapies to patients with respiratory diseases." 
 
   About Verona Pharma plc 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercialising innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. 
 
   Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, 
dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as 
both a bronchodilator and an anti-inflammatory agent in a single 
compound. Verona Pharma is developing RPL554 for the treatment of 
chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), 
and potentially asthma. 
 
   Forward-Looking Statements 
 
   This press release contains forward-looking statements. All statements 
contained in this press release that do not relate to matters of 
historical fact should be considered forward-looking statements. 
 
   These forward-looking statements are based on management's current 
expectations. These statements are neither promises nor guarantees, but 
involve known and unknown risks, uncertainties and other important 
factors that may cause our actual results, performance or achievements 
to be materially different from our expectations expressed or implied by 
the forward-looking statements, including, but not limited to, 
statements regarding advancing our regulatory plans in the U.S. and 
Europe and delivering new therapies to patients with respiratory 
diseases. 
 
   These and other important factors under the caption "Risk Factors" in 
our final prospectus filed with the Securities and Exchange Commission 
("SEC") on April 28, 2017 relating to our Registration Statement on Form 
F-1, and our other reports filed with the SEC, could cause actual 
results to differ materially from those indicated by the forward-looking 
statements made in this press release. Any such forward-looking 
statements represent management's estimates as of the date of this press 
release. While we may elect to update such forward-looking statements at 
some point in the future, we disclaim any obligation to do so, even if 
subsequent events cause our views to change. These forward-looking 
statements should not be relied upon as representing our views as of any 
date subsequent to the date of this press release. 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                              Tel: [phone] 
Jan-Anders Karlsson, Chief Executive           [e-mail] 
Officer 
 
FTI Consulting (UK Media and Investor          Tel: [phone] 
Enquiries) 
Simon Conway / Stephanie Cuthbert /            [e-mail] 
Natalie Garland-Collins 
 
ICR, Inc. (US Media and Investor Enquiries) 
Darcie Robinson                                Tel: [phone] 
                                               [e-mail] 
Stephanie Carrington                           Tel: [phone] 
                                               [e-mail] 
 
 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Verona Pharma plc via Globenewswire 
 
 
  http://www.veronapharma.com/ 
 

(END) Dow Jones Newswires

June 22, 2017 07:00 ET (11:00 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.